KR20120038494A - 개선된 항-혈청 알부민 결합 단일 가변 도메인 - Google Patents

개선된 항-혈청 알부민 결합 단일 가변 도메인 Download PDF

Info

Publication number
KR20120038494A
KR20120038494A KR1020127003939A KR20127003939A KR20120038494A KR 20120038494 A KR20120038494 A KR 20120038494A KR 1020127003939 A KR1020127003939 A KR 1020127003939A KR 20127003939 A KR20127003939 A KR 20127003939A KR 20120038494 A KR20120038494 A KR 20120038494A
Authority
KR
South Korea
Prior art keywords
ser
gly
leu
ala
val
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
KR1020127003939A
Other languages
English (en)
Korean (ko)
Inventor
에드워드 코울스톡
엘레나 데 안젤리스
하이췬 리우
올리베르 숀
Original Assignee
글락소 그룹 리미티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 글락소 그룹 리미티드 filed Critical 글락소 그룹 리미티드
Publication of KR20120038494A publication Critical patent/KR20120038494A/ko
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/31—Fusion polypeptide fusions, other than Fc, for prolonged plasma life, e.g. albumin

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Microbiology (AREA)
  • Veterinary Medicine (AREA)
  • Mycology (AREA)
  • Physics & Mathematics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Plant Pathology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
KR1020127003939A 2009-07-16 2010-07-14 개선된 항-혈청 알부민 결합 단일 가변 도메인 Withdrawn KR20120038494A (ko)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US22602809P 2009-07-16 2009-07-16
US61/226,028 2009-07-16
US30755410P 2010-02-24 2010-02-24
US61/307,554 2010-02-24

Publications (1)

Publication Number Publication Date
KR20120038494A true KR20120038494A (ko) 2012-04-23

Family

ID=42829253

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020127003939A Withdrawn KR20120038494A (ko) 2009-07-16 2010-07-14 개선된 항-혈청 알부민 결합 단일 가변 도메인

Country Status (15)

Country Link
US (2) US8679496B2 (enExample)
EP (1) EP2454285A2 (enExample)
JP (1) JP2012532620A (enExample)
KR (1) KR20120038494A (enExample)
CN (1) CN102574914A (enExample)
AU (1) AU2010272590B2 (enExample)
BR (1) BR112012001681A2 (enExample)
CA (1) CA2768462A1 (enExample)
EA (1) EA201270174A1 (enExample)
IL (1) IL217520A0 (enExample)
IN (1) IN2012DN00640A (enExample)
MX (1) MX2012000765A (enExample)
SG (1) SG177601A1 (enExample)
WO (1) WO2011006915A2 (enExample)
ZA (1) ZA201200276B (enExample)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20190091524A (ko) * 2016-12-07 2019-08-06 아블린쓰 엔.브이. 개선된 혈청 알부민 결합성 면역글로불린 단일 가변 도메인
KR20190104608A (ko) * 2017-01-17 2019-09-10 아블린쓰 엔.브이. 개선된 혈청 알부민 결합제
KR20190104609A (ko) * 2017-01-17 2019-09-10 아블린쓰 엔.브이. 개선된 혈청 알부민 결합제

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BRPI1008014A2 (pt) * 2009-02-19 2016-10-04 Glaxo Group Ltd domínio variável simples, ligante multiespecífico, antagonistas de tnfr1, e de receptor de tnf-alfa, uso do agonista de tnfr, antagonista anti-tnfr1, polipeptídeo ou ligante multiespecífico, método para tratar e/ou prevenir uma condição ou doença, ácido nucleico, vetor, e, hospedeiro
MX2012000765A (es) * 2009-07-16 2012-02-13 Glaxo Group Ltd Dominios variables sencillos de union de albumina anti-suero mejorados.
EP2603522A1 (en) * 2010-08-13 2013-06-19 GlaxoSmithKline Intellectual Property Development Limited Improved anti-serum albumin binding variants
WO2012072731A2 (en) * 2010-12-01 2012-06-07 Glaxo Group Limited Improved anti-serum albumin binding single variable domains
BR112014011304B1 (pt) 2011-11-11 2022-03-03 UCB Biopharma SRL Anticorpos de ligação com albumina e fragmentos de ligação dos mesmos, proteína de fusão de anticorpo bi-específico, polinucleotídeo, célula hospedeira, processo de produção de anticorpo ou fragamento do mesmo, formulação farmacêutica e uso
GB201200563D0 (en) * 2012-01-13 2012-02-29 Imp Innovations Ltd Binding molecule
WO2017041114A2 (en) * 2015-09-03 2017-03-09 The Children's Mercy Hospital Anti-nicotinamide phosphoribosyltransferase antibody genes and methods of use thereof
NO2768984T3 (enExample) 2015-11-12 2018-06-09
EP3374392B1 (en) * 2015-11-13 2021-11-24 Ablynx NV Improved serum albumin-binding immunoglobulin variable domains
BR112018010085A2 (pt) 2015-11-18 2018-11-13 Merck Sharp & Dohme ligantes de pd1/ctla4
CA3132021C (en) 2015-11-18 2024-03-12 Merck Sharp & Dohme Corp. Pd1 and/or lag3 binders
EA038179B1 (ru) 2015-11-18 2021-07-20 Мерк Шарп И Доум Корп. Ctla4-связывающие вещества
CA3005488A1 (en) 2015-11-18 2017-05-26 Ablynx Nv Improved serum albumin binders
WO2017201340A2 (en) 2016-05-18 2017-11-23 Modernatx, Inc. Polynucleotides encoding relaxin
HUE070957T2 (hu) 2017-02-16 2025-07-28 Sonnet Biotherapeutics Inc Albuminkötõ domén fúziós fehérjék
EP3470426A1 (en) 2017-10-10 2019-04-17 Numab Therapeutics AG Multispecific antibody
EP3694873A1 (en) 2017-10-10 2020-08-19 Numab Therapeutics AG Multispecific antibody
TW202045545A (zh) * 2019-02-22 2020-12-16 美商安維塔生物科學股份有限公司 白蛋白結合抗體及其用途
EP3816185A1 (en) 2019-11-04 2021-05-05 Numab Therapeutics AG Multispecific antibody directed against pd-l1 and a tumor-associated antigen
GB201919061D0 (en) 2019-12-20 2020-02-05 Ucb Biopharma Sprl Multi-specific antibody
US20230293647A1 (en) 2020-04-09 2023-09-21 Autolus Limited Polypeptide
GB202007441D0 (en) 2020-05-19 2020-07-01 Autolus Ltd Polypeptide
EP3915580A1 (en) 2020-05-29 2021-12-01 Numab Therapeutics AG Multispecific antibody
IT202000013006A1 (it) * 2020-06-01 2021-12-01 Bioreweal S R L Processo per la produzione biologica di idrogeno e/o di metano mediante assorbimento e conversione biologica di anidride carbonica.
EP3988568A1 (en) 2020-10-21 2022-04-27 Numab Therapeutics AG Combination treatment
PE20231953A1 (es) 2020-12-07 2023-12-06 UCB Biopharma SRL Anticuerpos multiespecificos y combinaciones de anticuerpos
KR20230166075A (ko) 2021-02-02 2023-12-06 누맙 세러퓨틱스 아게 Ror1 및 cd3에 대한 특이성을 가지는 다중 특이적 항체
EP4183800A1 (en) 2021-11-19 2023-05-24 Medizinische Hochschule Hannover Novel sars-cov-2 neutralizing antibodies
WO2024038095A1 (en) 2022-08-16 2024-02-22 Iome Bio NOVEL ANTI-RGMb ANTIBODIES
CN120712282A (zh) 2023-02-17 2025-09-26 阿布林克斯有限公司 结合新生儿fc受体的多肽
WO2025061919A1 (en) 2023-09-22 2025-03-27 Ablynx Nv Bi- and multivalent albumin binders
US12134635B1 (en) 2023-12-29 2024-11-05 Sonnet BioTherapeutics, Inc. Interleukin 18 (IL-18) variants and fusion proteins comprising same
US12459994B2 (en) 2024-04-12 2025-11-04 Paragon Therapeutics, Inc. Albumin binding proteins and methods of use

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL127127A0 (en) 1998-11-18 1999-09-22 Peptor Ltd Small functional units of antibody heavy chain variable regions
WO2002102973A2 (en) * 2001-06-20 2002-12-27 Prochon Biotech Ltd. Antibodies that block receptor protein tyrosine kinase activation, methods of screening for and uses thereof
US20100081792A1 (en) * 2001-06-28 2010-04-01 Smithkline Beecham Corporation Ligand
DE60305919T2 (de) 2002-06-28 2007-01-18 Domantis Limited, Cambridge Dual-specifische liganden mit erhöhter halbwertszeit
US9321832B2 (en) 2002-06-28 2016-04-26 Domantis Limited Ligand
ATE479760T1 (de) 2004-03-24 2010-09-15 Domantis Ltd Universelles signalpeptid gas1
BRPI0511755A (pt) 2004-06-01 2008-01-02 Domantis Ltd composições, fusões e conjugados de drogas e métodos de produção, tratamento e utilização
US7563443B2 (en) * 2004-09-17 2009-07-21 Domantis Limited Monovalent anti-CD40L antibody polypeptides and compositions thereof
WO2006059106A2 (en) 2004-12-02 2006-06-08 Domantis Limited Bispecific domain antibodies targeting serum albumin and glp-1 or pyy
GB0521621D0 (en) * 2005-10-24 2005-11-30 Domantis Ltd Tumor necrosis factor receptor 1 antagonists for treating respiratory diseases
AU2006321364B2 (en) * 2005-12-01 2011-11-10 Domantis Limited Noncompetitive domain antibody formats that bind Interleukin 1 Receptor type 1
CA2629850A1 (en) * 2005-12-01 2007-06-07 Domantis Limited Competitive domain antibody formats that bind interleukin 1 receptor type 1
TW200804425A (en) * 2005-12-06 2008-01-16 Domantis Ltd Ligands that have binding specificity for EGFR and/or VEGF and methods of use therefor
AU2007209201A1 (en) 2006-01-24 2007-08-02 Domantis Limited Fusion proteins that contain natural junctions
BRPI0710572A2 (pt) * 2006-01-24 2013-01-08 Domantis Ltd ligante, uso do ligante, mÉtodos para o tratamento de uma doenÇa alÉrgica, de asma e de cÂncer, para a inibiÇço de uma resposta imune do tipo th2, e administraÇço de tratamento anti-il-4 e tratamento anti-il-13, composiÇço farmacÊutica, dispositivo de dispensaÇço de droga, Ácido nucleico isolado ou recombinante, vetor, cÉlula hospedeira, mÉtodos para a produÇço de um ligante e de inibiÇço da proliferaÇço de cÉlulas
CA2683791A1 (en) 2007-06-06 2008-12-11 Domantis Limited Polypeptides, antibody variable domains & antagonists
WO2009149143A1 (en) * 2008-06-03 2009-12-10 E. I. Du Pont De Nemours And Company Adhesion of polyamides to epoxy resins
US8906035B2 (en) * 2008-06-04 2014-12-09 Ethicon Endo-Surgery, Inc. Endoscopic drop off bag
EP2297315A2 (en) * 2008-06-06 2011-03-23 Danisco US Inc. Compositions and methods comprising variant microbial proteases
US10198891B2 (en) * 2008-06-06 2019-02-05 Epona Llc System and method for regulating fuel transactions
MX2012000765A (es) * 2009-07-16 2012-02-13 Glaxo Group Ltd Dominios variables sencillos de union de albumina anti-suero mejorados.

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20190091524A (ko) * 2016-12-07 2019-08-06 아블린쓰 엔.브이. 개선된 혈청 알부민 결합성 면역글로불린 단일 가변 도메인
KR20190104608A (ko) * 2017-01-17 2019-09-10 아블린쓰 엔.브이. 개선된 혈청 알부민 결합제
KR20190104609A (ko) * 2017-01-17 2019-09-10 아블린쓰 엔.브이. 개선된 혈청 알부민 결합제
US11897944B2 (en) 2017-01-17 2024-02-13 Ablynx N.V. Immunoglobulin single variable domain (ISVD) capable of binding to serum albumin

Also Published As

Publication number Publication date
JP2012532620A (ja) 2012-12-20
WO2011006915A2 (en) 2011-01-20
CA2768462A1 (en) 2011-01-20
IN2012DN00640A (enExample) 2015-08-21
ZA201200276B (en) 2012-09-26
US8679496B2 (en) 2014-03-25
WO2011006915A3 (en) 2011-03-03
US20120114647A1 (en) 2012-05-10
SG177601A1 (en) 2012-02-28
AU2010272590B2 (en) 2013-10-10
US20140140996A1 (en) 2014-05-22
CN102574914A (zh) 2012-07-11
MX2012000765A (es) 2012-02-13
EP2454285A2 (en) 2012-05-23
IL217520A0 (en) 2012-02-29
AU2010272590A1 (en) 2012-02-02
EA201270174A1 (ru) 2012-07-30
BR112012001681A2 (pt) 2019-09-24

Similar Documents

Publication Publication Date Title
AU2010272590B2 (en) Improved anti-serum albumin binding single variable domains
JP5766616B2 (ja) 改良型抗血清アルブミン結合変異体
JP6100315B2 (ja) 改良型抗血清アルブミン結合変異体
US20130129746A1 (en) Anti-serum albumin binding variants
JP2014501515A (ja) 改良された抗血清アルブミン結合単一可変ドメイン
AU2014200157A1 (en) Improved anti-serum albumin binding single variable domains
HK40023197A (en) Improved anti-serum albumin binding variants

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

PC1203 Withdrawal of no request for examination

St.27 status event code: N-1-6-B10-B12-nap-PC1203

WITN Application deemed withdrawn, e.g. because no request for examination was filed or no examination fee was paid
R18-X000 Changes to party contact information recorded

St.27 status event code: A-3-3-R10-R18-oth-X000